Colivelin
Also known as: ADNF-Humanin hybrid
Colivelin simultaneously activates an ADNF-mediated CaMKIV pathway and a Humanin-mediated JAK2/STAT3 pathway to suppress neuronal death in cell and rodent models.
- Drug class
- Synthetic neuroprotective hybrid peptide (ADNF + Humanin derivative)
- Primary targets
- Humanin receptor / JAK2-STAT3 pro-survival pathway, ADNF / Ca2+-calmodulin-dependent protein kinase IV (CaMKIV) pathway
- Dose reference
- No established human dose; preclinical rodent studies used roughly 10 pmol to 1 nmol given intracerebroventricularly, plus intraperitoneal and intranasal experiments (research figures only, not recommendations).
- Half-life
- Not established in humans; expected to be short as an unmodified peptide.
- Developer / origin
- Nishimoto, Matsuoka, Chiba and colleagues, Keio University School of Medicine (Tokyo)
- Reference year
- 2005
- Evidence score
- 2/5 - Preclinical only
Preclinical only
Colivelin shows consistent, potent neuroprotection in cell-culture and rodent models of Alzheimer's disease and ALS, but there is no human clinical or safety evidence and it has never entered registered human trials.
Mostly animal, ex vivo, cell, or indirect evidence.
Evidence basis
- Femtomolar neuroprotection against amyloid-beta and familial AD mutant toxicity in vitro (Chiba et al., J Neurosci 2005)
- Improved memory and reduced hippocampal neuronal loss in Alzheimer's mouse models via ICV, IP and intranasal routes (Chiba 2005; Yamada 2008)
- Prolonged survival and improved motor performance in G93A-SOD1 ALS mice (Chiba et al., BBRC 2006)
- No human pharmacokinetic, efficacy, or safety data; no registered clinical trials despite ~two decades of preclinical work
Key references
- PubMedDevelopment of a femtomolar-acting humanin derivative named colivelin (Chiba et al., J Neurosci 2005)
- PubMedColivelin prolongs survival of an ALS model mouse (Chiba et al., BBRC 2006)
- PubMedNasal Colivelin treatment ameliorates memory impairment related to Alzheimer's disease (Yamada et al., Neuropsychopharmacology 2008)
How to read this entry
Dose references and half-life values are pulled from trial protocols, labels, reviews, or published summaries where available. They are context for research and comparison, not a personal dosing recommendation.
Status matters: approved drugs have regulated indications; investigational compounds are still being studied; research-only peptides do not have established human dosing, safety, or efficacy for consumer use.
Colivelin guides
Read the matching guide or adjacent research pages for more context.
Peptide calculators
Use calculators for concentration, unit conversion and repeated-dose accumulation math.
Compare with related peptides
Stay inside the same research category and compare mechanism, status and evidence quality.
GHK-Cu
Copper tripeptide-1
Naturally occurring tripeptide bound to copper. Studied for wound healing, skin remodeling and gene-expression effects related to tissue repair.
Humanin
HN, MTRNR2
Humanin is a 24-amino-acid mitochondrial-derived peptide that limits stress-induced apoptosis by binding pro-apoptotic proteins (BAX, Bid/Bim) and IGFBP-3 intracellularly and by signaling extracellularly through FPR2/FPRL1 and the CNTFR/WSX-1/gp130 complex to activate JAK2/STAT3, ERK1/2 and AKT survival pathways.
Thymalin
thymus polypeptide fraction
Thymalin is a calf-thymus polypeptide complex proposed to act as an immunomodulator that promotes T-lymphocyte differentiation and maturation and normalizes cytokine and immune-cell balance, though its precise molecular receptor or target remains undefined.
Thymogen
Glutamyl-Tryptophan, gamma-glutamyl-tryptophan
Thymogen is a synthetic L-glutamyl-L-tryptophan dipeptide that acts as a thymic-peptide immunomodulator, promoting T-lymphocyte differentiation and peptide-MHC recognition, shifting IL-2 and interferon cytokine output, and enhancing neutrophil chemotaxis and phagocytosis.
Category hub
Open the category page for the full comparison table and FAQ.